Sanofi

ASLAN Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, April 28, 2023
Abstract, Purchasing, Partnership, Executive director, Leo Pharma, Marketing, ISID, ASLN, ADS, TMO, Atopic dermatitis, Thermo Fisher Scientific, Neck, Associate, HCP, Sale, Yale School of Medicine, Alopecia areata, Development, Paul Khavari, Type 2, Journal, MD, Patient, Investment, International Society for Infectious Diseases, SAN, Autoimmune disease, Sanofi, Power purchase agreement, IL4R, Tralokinumab, Research, AD, NYSE, Safety, Pharmaceutical industry, Cryptocurrency, Video game, Head, Dermatology, AA

“We have also advanced farudodstat into a Phase 2a, proof-of-concept study in alopecia areata (AA) expected to commence enrollment in the second quarter of 2023.

Key Points: 
  • “We have also advanced farudodstat into a Phase 2a, proof-of-concept study in alopecia areata (AA) expected to commence enrollment in the second quarter of 2023.
  • The trial will recruit around 60 AA patients in the US and enrollment is expected to begin in the second quarter of 2023.
  • Research and development expenses were $14.1 million in the first quarter of 2023 compared to $9.4 million in the first quarter of 2022.
  • General and administrative expenses were $4.0 million in the first quarter of 2023 compared to $2.5 million in the first quarter of 2022.

Flatiron Health Embarks on Strategic Collaboration with Sanofi to Make Clinical Trials More Efficient by Streamlining Data Acquisition at the Point of Care

Retrieved on: 
Monday, May 1, 2023
Managed Care, Software, Research, Data Management, Oncology, Technology, Hospitals, Genetics, Health Technology, Clinical Trials, Science, Biotechnology, Health, Clinical trial, Cancer, Multimedia, Community, Acquisition, Patient, EHR, Clinical research, Flatiron, ChromeOS, EDC, Pharmaceutical industry, Medical imaging, Sanofi

View the full release here: https://www.businesswire.com/news/home/20230501005091/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230501005091/en/
    The multi-study collaboration between Sanofi and Flatiron will focus on improving clinical trial data acquisition, delivery, and quality through site-facing technology that digitally transfers data captured in the electronic health record (EHR) directly into the electronic data capture (EDC) system through Flatiron Health’s EHR-to-EDC product, Flatiron Clinical Pipe™.
  • By focusing on the area of oncology, this collaboration intends to accelerate development of new treatments and help more people with cancer.
  • Sanofi and Flatiron will collaborate on data standards and mapping to expand the volume and types of data eligible for automated transfer.
  • “We’re incredibly excited to collaborate and partner with forward-thinkers like Sanofi, who share our aspiration to leverage data and technology to transform clinical research.

Maze Therapeutics Announces Exclusive Worldwide License Agreement with Sanofi for MZE001, an Oral Substrate Reduction Therapy for the Treatment of Pompe Disease

Retrieved on: 
Monday, May 1, 2023
Research, Neurology, Genetics, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Science, Glycogen, Intellectual property, Partnership, Therapy, Glycogen storage disease type II, Patient, Compass, Pharmaceutical industry, PBMC, Sanofi, Maze

MZE001, designed and developed by Maze, is an oral GYS1 inhibitor that aims to address Pompe disease by limiting disease-causing glycogen accumulation.

Key Points: 
  • MZE001, designed and developed by Maze, is an oral GYS1 inhibitor that aims to address Pompe disease by limiting disease-causing glycogen accumulation.
  • “People with Pompe disease continue to need additional treatment options for this life-threatening condition.
  • “This agreement provides important validation for the potential of our Compass platform to elucidate novel, genetic insights that inform the discovery and advancement of new medicines.
  • “MZE001 has demonstrated meaningful preclinical proof of concept by inhibiting GYS1, a validated, genetic driver of Pompe disease.

Gold Sponsor, Axtria Presents a Thought-Provoking Workshop on “Does Geography Affect Your Health?” and Six Additional HEOR/RWE Studies at ISPOR 2023

Retrieved on: 
Thursday, April 27, 2023
Doctor of Philosophy, Regeneron Pharmaceuticals, ISPOR, Research, Medicine, Social, Patient, Randomized controlled trial, Geography, RWE, Health, Sanofi

Axtria’s Won Chan Lee, Ph.D., Principal, RWE & HEOR, will lead a workshop titled “ Does Geography Affect Your Health?

Key Points: 
  • Axtria’s Won Chan Lee, Ph.D., Principal, RWE & HEOR, will lead a workshop titled “ Does Geography Affect Your Health?
  • Insights derived from integrating geography-based social determinants of health (SDoH) with patient-level real-world data will be shared with the audience.
  • Lee will be joined by his colleague, Jennifer Ken-Opurum, Ph.D., along with representatives from Sanofi and Regeneron.
  • Axtria will also present six posters at ISPOR 2023 .

Press Release: Sanofi completes acquisition of Provention Bio, Inc.

Retrieved on: 
Thursday, April 27, 2023
Centerview Partners, PJT Partners, Eastern Time Zone, BofA Securities, Weil, Gotshal & Manges, General Medicine Faculty of RostGMU (Rostov State Medical University), Ropes & Gray, Delaware General Corporation Law, Acquisition, Patient, Growth, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Cryptocurrency, Sanofi

Sanofi completes acquisition of Provention Bio, Inc.

Key Points: 
  • Sanofi completes acquisition of Provention Bio, Inc.
    Paris, April 27 2023.
  • Sanofi announced today the completion of its acquisit i on of Provention Bio, Inc .
  • (“Provention Bio”).
  • Following its acceptance of the tendered shares, Sanofi completed its acquisition of Provention Bio through the merger of a wholly owned subsidiary of Sanofi with and into Provention Bio, pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with Provention Bio continuing as the surviving corporation and becoming an indirect, wholly owned subsidiary of Sanofi.

Press Release: Strong Q1 growth driven by Specialty Care, Vaccines and CHC

Retrieved on: 
Thursday, April 27, 2023
Sanofi, Chronic obstructive pulmonary disease, CHC, EPS, RSV, Vaccine, Patent, CER, Coordinated Specialty Care, CSU, Prestige Consumer Healthcare, Pharmaceutical industry

Applying average April 2023 exchange rates, the currency impact on 2023 business EPS is estimated between -5.5% to -6.5%

Key Points: 
  • Applying average April 2023 exchange rates, the currency impact on 2023 business EPS is estimated between -5.5% to -6.5%
    “We have started 2023 with strong results, delivering double-digit sales growth across our Specialty Care, Vaccines and Consumer Healthcare businesses.
  • Dupixent® continues its compelling performance and is on track to achieve its €10 billion sales objective for this year.
  • The unique product profile of Dupixent®was further underscored by highly positive pivotal results in uncontrolled chronic obstructive pulmonary disease, which we are looking forward to discuss with regulators.
  • We are also advancing our early-to-mid stage pipeline and plan to feature several promising candidates at upcoming R&D investor events.

Seagen Reports First Quarter 2023 Financial Results

Retrieved on: 
Thursday, April 27, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Trastuzumab, Head, NCCN, RAS, Patient, Merck, Spacecraft, BLA, Inc., SGN, Lymphoma, CDE, Accelerated approval (FDA), ADC, Gender representation on corporate boards of directors, Growth, PD-1, Center for Drug Evaluation and Research, FDA, NMPA, Bladder cancer, Hodgkin lymphoma, Abstract, ODE, AACR, American Association for Cancer Research, ADCETRIS, Cohort study, Immunotherapy, National Medical Products Administration, Sanofi, Brentuximab vedotin, Pembrolizumab, Abstract (summary), Clinical trial, Cisplatin, Category, Part, Neck, CEACAM5, ASCO, American Society of Clinical Oncology, Annual general meeting, Society, Pfizer, Pharmaceutical industry, Seagen

Seagen Inc. (Nasdaq:SGEN) (Seagen or the Company) reported financial results today for the first quarter ended March 31, 2023.

Key Points: 
  • Seagen Inc. (Nasdaq:SGEN) (Seagen or the Company) reported financial results today for the first quarter ended March 31, 2023.
  • “Seagen delivered strong performance in the first quarter, with significant growth of 22 percent for both total revenue and net product sales, compared to 2022, driven by our multi-product commercial portfolio,” said David Epstein, Chief Executive Officer of Seagen.
  • Proposed Acquisition of Seagen by Pfizer: In March 2023, Seagen and Pfizer announced they have entered into a definitive merger agreement under which, on the terms and subject to the conditions thereof, Pfizer will acquire Seagen for $229 in cash per Seagen share for a total enterprise value of $43 billion.
  • Revenues: Total revenues for the first quarter of 2023 were $520 million, compared to $426 million for the same period in 2022, primarily driven by growth in net product sales.

LifeSci Communications Bolsters Leadership Team

Retrieved on: 
Wednesday, April 26, 2023
LSC, Bristol Myers Squibb, Edwards Lifesciences, Wheeler, Omnicom Group, Patient, Bird, Sanofi, Growth, Merck, AofA—International Meeting on Combinatorial, Probabilistic, and Asymptotic Methods in the Analysis of Algorithms, Environment, Talazoparib, Pharmaceutical industry, Science, Pfizer

NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- LifeSci Communications (LSC) today announced the appointment of Tim Bird as executive vice president, client services and Sarah Wheeler , senior vice president, medical communications.

Key Points: 
  • NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- LifeSci Communications (LSC) today announced the appointment of Tim Bird as executive vice president, client services and Sarah Wheeler , senior vice president, medical communications.
  • Bird will lead LifeSci’s growing client roster and expanding team; and Wheeler will help accelerate the growth of the agency’s medical communication services.
  • He brings more than 30 years of experience in brand communications, corporate communications and reputation building.
  • “It’s exciting to leverage our unique heritage in integrated communications to support novel advances for patients.”
    Previously, Wheeler was executive vice president at BGB Group.

C4X Discovery Holdings plc: Half-year results for the six months ended 31 January 2023

Retrieved on: 
Wednesday, April 26, 2023
Net, Total, AIM, Garvan Institute of Medical Research, Drug discovery, NRF2, Personalized medicine, Cancer, AstraZeneca, Inflammatory bowel disease, Total loss, Webcast, Sanofi, Third, Johnson & Johnson, Substance use disorder, Medical research, Inflammation, BST, Pharmaceutical industry, Cryptocurrency, Indivior

Up to $402 million AstraZeneca deal for NRF2 Activator programme; Third global out-licensing deal executed

Key Points: 
  • Up to $402 million AstraZeneca deal for NRF2 Activator programme; Third global out-licensing deal executed
    MANCHESTER, United Kingdom, April 26, 2023 (GLOBE NEWSWIRE) -- C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces its half-year results for the six months ended 31 January 2023.
  • "I'm excited that following a review of our expertise and previous successes, our strategy is now focused on treatments for immuno-inflammatory diseases.
  • Indivior's Phase 1 multiple ascending dose clinical trial of C4XD's oral Orexin-1 receptor antagonist, C4X_3256 (INDV-2000), for substance use disorder is ongoing.
  • C4XD signed an exclusive worldwide licensing agreement with AstraZeneca in November 2022, worth up to $402 million, for its NRF2 Activator programme.

Press Release: Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention Bio, Inc.

Retrieved on: 
Wednesday, April 26, 2023
Eastern Time Zone, Telephone, Tax, Hart–Scott–Rodino Antitrust Improvements Act, Bangladesh Securities and Exchange Commission, Acquisition, Broker, Sanofi, Security (finance), Share (finance)

Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention Bio, Inc.

Key Points: 
  • Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention Bio, Inc.
    Paris, France – April 26, 2023 – Sanofi announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), applicable to Sanofi’s proposed acquisition of Provention Bio, Inc. (“Provention Bio”, NASDAQ: PRVB) has expired.
  • As a result of the expiration of the waiting period under the HSR Act, the condition to the Offer relating to the expiration or termination of the waiting period under the HSR Act has been satisfied.
  • The Offer is scheduled to expire at one minute after 11:59 P.M., Eastern Time, on April 26, 2023.
  • Innisfree M&A Incorporated is acting as information agent for the tender offer.